A U.S. appeals court decision blocks mailing of abortion medication, requiring in-person distribution and reshaping national abortion access. A federal appeals court has significantly restricted access to abortion medication in the United States, ruling that the abortion pill mifepristone can no longer be mailed and must instead be dispensed in person at clinics.
Table Of Content
The unanimous decision from a three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans overturns federal Food and Drug Administration (FDA) rules that previously allowed telehealth prescriptions and mail delivery of the drug.
The ruling marks one of the most significant shifts in U.S. abortion policy since the Supreme Court’s 2022 decision that overturned Roe v. Wade and enabled states to enforce abortion bans.
Legal reasoning and state challenge
Judge Kyle Duncan, appointed by former President Donald Trump, supported Louisiana’s argument that mailing the drug undermines the state’s abortion ban.
The court stated that federal approval allowing mail distribution conflicts with Louisiana’s policy defining life as beginning at conception.
What is mifepristone?
Mifepristone, approved in 2000, is widely used in combination with misoprostol to end early pregnancies. It accounts for most abortions in the U.S., with a growing share conducted via telehealth.
Studies show telemedicine abortions have become especially important in states with strict abortion bans, sometimes allowing residents to avoid traveling out of state.
FDA regulation and scientific debate
The ruling breaks with long-standing judicial practice of deferring to FDA scientific authority.
The FDA had previously required in-person prescriptions and certified physicians due to safety concerns but lifted many restrictions during the COVID-19 pandemic. The agency later affirmed that extensive research supported safe use without direct supervision.
GenBioPro, a manufacturer of generic mifepristone, criticized the ruling, saying it ignores decades of scientific evidence and safe use.
National impact
The decision extends beyond states with abortion bans, affecting telehealth prescriptions nationwide, including in states where abortion remains legal.
Civil rights groups warned the ruling could disproportionately harm rural communities, low-income patients, disabled individuals, and survivors of violence by reducing healthcare access.
Anti-abortion groups, however, praised the ruling as restoring oversight and protecting safety standards.
Next legal steps
The ruling is expected to be appealed to the U.S. Supreme Court. A related company has already requested an emergency pause, warning of immediate nationwide disruption if the order is enforced.
The Supreme Court previously upheld access to mifepristone in 2024 on procedural grounds but did not rule on its safety or legality directly.
- Source: AP